Loading organizations...
Key people at Black Point Group.
Black Point Group is a Maine-based investment firm focused on private and public equity investments in healthcare, technology, and science-based companies. The firm supports the creation and growth of ventures across various markets, with its portfolio companies collectively employing more than 20,000 people worldwide. Notable portfolio companies include IDEXX Laboratories and Covetrus, which generated over $4 billion in annual revenue and served 100,000 customers with 5,500 employees. The firm frequently co-invests alongside prominent venture capital and private equity groups, such as Venrock Associates, New Mountain Capital, and Polaris Venture Partners. A significant transaction for the group occurred in 2019 when portfolio company Vets First Choice merged to form Covetrus in a definitive agreement valued at $1.9 billion. Black Point Group was founded in 2002 by David Evans Shaw and Benjamin Shaw.
Key people at Black Point Group.
# Black Point Group: High-Level Overview
Black Point Group is a Portland, Maine-based private investment partnership focused on long-term value creation through active involvement in public and private growth companies.[1][3] Founded in 2007, the firm manages a diversified portfolio across healthcare, life sciences, technology, and internet sectors, with a particular emphasis on science-based companies.[1][2][4] The partnership leverages operational and investment expertise to support entrepreneurship while maintaining significant involvement in public service and impact investing initiatives.[3]
The firm's approach centers on hands-on value creation rather than passive capital deployment. Black Point Group combines traditional private equity and venture capital strategies, investing in both established growth companies and early-stage ventures. Beyond financial returns, the firm demonstrates a commitment to impact investing and community engagement, particularly in Maine's entrepreneurial ecosystem.[2][5]
Black Point Group was established in 2007 by David E. Shaw, who serves as a founding partner alongside Benjamin Shaw, Rhonda Wanser, and Kelly Cook.[5] David Shaw's background includes partnership at Venrock, the premier venture capital firm originally established as the venture capital arm of the Rockefeller family, providing him with deep expertise in scaling successful companies.[2]
The firm's founding coincided with a significant early investment: Black Point Group was part of the investment team that created Ikaria Holdings in 2007 through a $670 million cash and stock merger. Ikaria became a fully integrated critical care pharmaceutical company, and the investment demonstrated the partnership's ability to structure and execute large, transformative deals in the life sciences sector. When Ikaria was sold to Madison Dearborn for $1.6 billion in December 2013, Black Point Group's involvement validated its investment thesis and operational model.[2]
Black Point Group operates at the intersection of Maine's emerging innovation economy and national life sciences investment trends. The firm's focus on science-based companies positions it to benefit from increased venture capital interest in biotechnology, pharmaceuticals, and healthcare innovation—sectors that have attracted substantial institutional capital over the past two decades.
The partnership's emphasis on active operational involvement reflects a broader shift in private equity toward value creation through management expertise rather than financial engineering alone. By maintaining deep roots in Maine while accessing national networks through Venrock and other partnerships, Black Point Group bridges regional entrepreneurship with institutional capital flows.
The firm's commitment to impact investing and public service aligns with growing institutional demand for ESG-aligned investments and demonstrates how traditional private equity can integrate social objectives without compromising financial performance.
Black Point Group exemplifies a regionally-anchored, sector-focused investment model that combines financial discipline with community impact. As life sciences and healthcare innovation continue to attract capital, and as impact investing becomes increasingly mainstream, the firm's positioning in these domains suggests sustained relevance.
The partnership's future likely involves deepening its operational support capabilities in portfolio companies while expanding its influence in Maine's entrepreneurial ecosystem—potentially serving as a model for how regional investment firms can punch above their weight through specialization, network leverage, and hands-on value creation rather than asset scale alone.
